Advertisement
Pharma/Biotech News
Subscribe to Pharma/Biotech News
View Sample

FREE Email Newsletter

Daily news and top headlines for drug research professionals

EMA, FDA Grant Glioblastoma Drug Orphan Drug Designation

August 4, 2014 10:12 am | News | Comments

AbbVie announced the EMA and the FDA have granted orphan drug designation to AbbVie's investigational compound ABT-414, an anti-epidermal growth factor receptor antibody drug conjugate, which is being evaluated for safety and efficacy in patients with glioblastoma multiforme. Read more...

Capsaicin May Inhibit Gut Tumors

August 4, 2014 10:06 am | News | Comments

Researchers at the University of California, San Diego School of Medicine report that dietary capsaicin – the active ingredient in chili peppers – produces chronic activation of a receptor on cells lining the intestines of mice, triggering a reaction that ultimately reduces the risk of colorectal tumors. Read more...

Allergan Sues Valeant, Cries Fraud

August 4, 2014 10:00 am | by Linda A. Johnson, AP Business Writer | News | Comments

Botox and eye-drug maker Allergan is suing a Canadian drugmaker and a hedge fund over their hostile takeover attempt, alleging insider trading and other fraud before their plan became public, and Valeant and Pershing Square call Allergan's claims related to tender offer rules "baseless." Read more...

Advertisement

Sirona Biochem Synthesizes New Anti-Inflammatory

July 31, 2014 2:28 pm | News | Comments

Sirona Biochem Corp. announced the achievement of the first batch of compound in the joint venture with Bloom Burton & Co. Compounds developed within the framework of the joint venture (JV) will be entering development in the areas of rare inflammatory and infectious diseases. Read more...

BGI Buys Genome Mapping System

July 31, 2014 2:21 pm | News | Comments

BioNano Genomics announced the purchase of an Irys System by BGI, the world's largest genomics organization. BGI selected BioNano's platform to enable comprehensive exploration of human structural variation and to provide vastly improved assemblies for various organisms of interest, including those where no reference exists. Read more...

Replikin Count Predicts Ebola Outbreaks

July 31, 2014 2:14 pm | News | Comments

Replikins Ltd. released new data on changes in the gene structure of the Ebola virus showing that before the current outbreaks, the mean Ebola Reston gene Replikin Count between 1995 and 2002 was 1.1; the mean Replikin Count increased two-fold in 2010, three-fold in 2012, and sixteen-fold in 2013. Read more...

Transplantation Works Well in Immunodeficient Children

July 31, 2014 2:07 pm | News | Comments

Babies who are born with severe combined immunodeficiency can be successfully treated with a transplant of blood-forming stem cells, according to experts led by Memorial Sloan Kettering’s Richard O’Reilly, MD, a world-renowned pioneer in the development of transplant protocols. Read more...

Thyroid Cancer Drug Approved for Accelerated Assessment

July 31, 2014 1:59 pm | News | Comments

The European Medicines Agency has approved Eisai's request for accelerated assessment of the investigational oral multiple receptor tyrosine kinase inhibitor lenvatinib, for the treatment of patients with progressive radioiodine-refractory, differentiated thyroid cancer. Read more...

Advertisement

AFFiRiS, MJFF Make Progress on Parkinson's Vaccine

July 31, 2014 1:56 pm | News | Comments

AFFiRiS announced results of a Phase 1 clinical trial of PD01A, a vaccine against Parkinson's disease. PD01A is the first therapy against the protein alpha-synuclein, a promising Parkinson's drug target, to enter clinical testing. Read more...   

Kala Initiates Phase 2 Eye Drug Trials

July 31, 2014 1:43 pm | News | Comments

Kala Pharmaceuticals Inc. announced the initiation of two Phase 2 clinical trial to evaluate KP-121, the company’s loteprednol etabonate MPP (LE-MPP) drug product. Read more...                     

Cannabis Science to Test Multiple Strains for Clinical Development

July 31, 2014 1:36 pm | News | Comments

Cannabis Science Inc. announced that it has commenced production of multiple strains of cannabis and European Union certified hemp varieties to initiate scientific research to select the best strains for development of clinical drugs. Read more... 

Biorepository Management Today

July 31, 2014 1:21 pm | by Louise Rozik, Editor | Articles | Comments

Scientists are accustomed to the fickle nature of research, but sometimes it can get to even the most seasoned researcher. One especially poignant example – the Cancer Genome Atlas – starts with the completion of the Human Genome Project in 2003. Read more...

Gilead, Theraclone Partner on HIV Antibodies

July 31, 2014 9:46 am | News | Comments

Theraclone Sciences Inc. announced that it has entered into an agreement with Gilead Sciences Inc., under which Gilead received an exclusive license to develop and commercialize products incorporating Theraclone’s broadly neutralizing HIV-antibodies for therapeutic applications in HIV. Read more...

Advertisement

Cholesterol Drug Hits Primary Endpoint in Nine Trials

July 31, 2014 9:41 am | News | Comments

Sanofi and Regeneron announced that nine new Phase 3 ODYSSEY trials of alirocumab in people with hypercholesterolemia met their primary efficacy endpoint of a greater percent reduction from baseline in low-density lipoprotein cholesterol at 24 weeks compared to placebo or active comparator. Read more...

AstraZeneca, Almirall Strike Deal on Respiratory Franchise

July 31, 2014 9:17 am | News | Comments

AstraZeneca announced that it has entered an agreement to transfer to the company the rights to Almirall’s respiratory franchise for an initial consideration of $875 million on completion, and up to $1.22 billion in development, launch and sales-related milestones. Read more...

Illinois Medicaid Restricts Sovaldi Use

July 31, 2014 9:10 am | by Carla L. Johnson, AP Medical Writer | News | Comments

Facing ballooning costs for a $1,000 pill to treat hepatitis C, Illinois' Medicaid program is putting tight restrictions in place, including requiring patients to meet 25 criteria and get prior approval before the government program will pay for the new drug. Read more...

France is 17th Country to Allow Patient Enrollment in Head, Neck Cancer Trial

July 31, 2014 8:44 am | News | Comments

CEL-SCI Corp. announced that the French Agency for the Safety of Health Products has cleared the company to commence patient enrollment for its Phase 3 Head and Neck Cancer clinical trial of its investigational cancer immunotherapy treatment Multikine (Leukocyte Interleukin, Injection) in France. Read more...

Protein May Prevent Antibody-Mediated Transplant Rejection

July 31, 2014 8:40 am | News | Comments

A study presented at the 2014 World Transplant Congress evaluated the safety and efficacy of CSL Behring's C1 Inhibitor (C1-INH) concentrate in preventing antibody-mediated rejection following kidney transplants in highly sensitized patients. Read more...

CHMP Has More Issues with Weight Loss Drug

July 31, 2014 8:34 am | News | Comments

Orexigen Therapeutics Inc. announced it has received the Day 180 List of Outstanding Issues from the European Medicines Agency's Committee for Medicinal Products for Human Use for the NB32 (naltrexone sustained release (SR) / bupropion SR) Marketing Authorization Application. Read more...

Researchers ID New Malaria Vaccine Candidates

July 31, 2014 8:29 am | News | Comments

Researchers have discovered new vaccine targets that could help in the battle against malaria. Taking a new, large-scale approach to this search, researchers tested a library of proteins from the Plasmodium falciparum parasite with antibodies produced by the immune systems of a group of infected children. Read more...

Peptide Generates New Insulin-Producing Cells

July 31, 2014 8:23 am | News | Comments

A new study by researchers at Sanford-Burnham Medical Research Institute has found that a peptide called caerulein can convert existing cells in the pancreas into those cells destroyed in type 1 diabetes—insulin-producing beta cells. Read more...

Ebola Crisis Triggers Health Emergency

July 31, 2014 8:10 am | by Clarence Roy-Macaulay, Associated Press | News | Comments

The president of Sierra Leone declared a public health emergency as the Ebola crisis blamed for nearly 700 deaths deepened across West Africa, vowing to quarantine sick patients at home and conduct house-to-house searches for others who may have been exposed. Read more...

Profectus BioSciences Snags $3.5M from NIH for HIV Vaccines

July 30, 2014 2:41 pm | News | Comments

Profectus BioSciences announced the award of two SBIR grants totaling $3.5 million from the Division of AIDS, National Institute of Allergy and Infectious Diseases (NIAID), National Institutes of Health (NIH). Read more...        

FDA Approves Eylea for Third Indication

July 30, 2014 2:34 pm | News | Comments

Regeneron Pharmaceuticals Inc. announced that the FDA has approved Eylea (aflibercept) Injection for the treatment of Diabetic Macular Edema (DME). Read more...                          

Treatment Combo Benefits Lung Cancer Patients

July 30, 2014 2:04 pm | News | Comments

A combination of the EGFR-targeted anticancer therapeutics Gilotrif and Erbitux yielded clinical responses in 29% of patients who had lung cancer harboring epidermal growth factor receptor mutations that had stopped responding to other inhibitors, according to new data. Read more...

X
You may login with either your assigned username or your e-mail address.
The password field is case sensitive.
Loading